Contact A Lawyer
Near You

Contact us today for a complimentary consultation with a qualified attorney near you.

Bextra may have higher risk of stroke and heart attack

-October 18, 2004

Pfizer, Inc. announced two small clinical trials showed that heart bypass surgery patients taking its anti-inflammatory drug Bextra had a higher risk of stroke and heart attack. Bextra is a COX-2 inhibitor drug, part of the same class of drug as Merck & Co.'s recently recalled arthritis and pain relief drug Vioxx. Following the Vioxx recall, experts quickly warned that the increased risk of cardiovascular events may be a class - wide effect, bringing closer scrutiny on the two remaining COX-2 inhibitors on the market, Pfizer's Bextra and Celebrex.

Pfizer has also said it is updating Bextra labeling to reflect a stronger warning about a rare but serious skin reaction that can occur mainly in the first two weeks of drug therapy.

For more information on bextra and heart attacks, please contact us.


view more recent articles

Contact Us

Contact a Newsletter Recall Lawyer